The group notes that the FDA suspended in-person requirements for many other drugs during the pandemic, including opioids, but kept them in place for mifepristone.Read More

The group notes that the FDA suspended in-person requirements for many other drugs during the pandemic, including opioids, but kept them in place for mifepristone.Read More